Furazolidone
FDA-approved product (tablet, oral), marketed as Furoxone.
- Registered studies
- 49
- Lab records
- 2
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Furazolidone. Its therapeutic class is shown instead.
- WHO therapeutic group
- Other antiinfectives and antiseptics
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC G01AX06
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA23.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae16.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis91.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
49registered studies name this medicine, for any condition. See them below.
Experimental
- M. tuberculosis: measured active in 2 of 2 lab records
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Furazolidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AfamelanotideExisting use: Erythropoietic protoporphyria65.1% AI-predicted activityagainst MRSA23 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives64.9% AI-predicted activityagainst MRSALab records exist50+ registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more64.9% AI-predicted activityagainst MRSA50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder64.8% AI-predicted activityagainst MRSA1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more64.8% AI-predicted activityagainst MRSA15 registered studies
- Rimegepant SulfateExisting use: Migraine disorder64.7% AI-predicted activityagainst MRSA50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency64.6% AI-predicted activityagainst MRSA7 registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction64.5% AI-predicted activityagainst MRSA1 registered study
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma64.4% AI-predicted activityagainst MRSA3 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis64.3% AI-predicted activityagainst MRSA50+ registered studies
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor64.2% AI-predicted activityagainst MRSA1 registered study
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection
NCT01805934 · start 2012-05
Registered record
- Registry ID
- NCT01805934
- Conditions
- Rescue Therapy for Helicobacter Pylori
- Interventions
- RBLF; RA
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-05
- Completion
- 2013-02
- Enrolment
- 114
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRescue Therapy for Helicobacter PyloriInterventionRBLF; RAPhasePhase 2Registry statusCompletedHelicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
NCT01730352 · start 2008-10
Registered record
- Registry ID
- NCT01730352
- Conditions
- Immune Thrombocytopenic Purpura; Helicobacter Pylori Infection
- Interventions
- H. pylori triple therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2012-03
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImmune Thrombocytopenic Purpura; Helicobacter Pylori InfectionInterventionH. pylori triple therapyPhasePhase 2 / Phase 3Registry statusCompletedQuadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection
NCT00520949 · start 2006-10
Registered record
- Registry ID
- NCT00520949
- Conditions
- Treatment of Helicobacter Pylori
- Interventions
- Augmentin (Amoxicillin-clavulanic); Furoxone (furazolidone); Cebes (colloidal bismuth subcitrate); Esso (esomeprazole)
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-10
- Completion
- 2008-06
- Enrolment
- 176
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTreatment of Helicobacter PyloriInterventionAugmentin (Amoxicillin-clavulanic); Furoxone (furazolidone); Cebes (colloidal bismuth subcitrate); Esso (esomeprazole)PhaseNot applicableRegistry statusCompletedHome Based Child Care to Reduce Mortality and Malnutrition in Tribal Children of Melghat, India: CRCT
NCT02473796 · start 2004-01
Registered record
- Registry ID
- NCT02473796
- Conditions
- Acute Respiratory Tract Infections; Diarrhea; Malaria; Neonatal Sepsis; Birth Asphyxia
- Interventions
- Home based child care
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-01
- Completion
- 2010-04
- Enrolment
- 7,594
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Respiratory Tract Infections; Diarrhea; Malaria; Neonatal Sepsis +1 moreInterventionHome based child carePhaseNot applicableRegistry statusCompleted